Literature DB >> 26627823

Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function.

Li Ren1, Amanda Campbell2, Huiqing Fang2, Shalini Gautam2, Saranya Elavazhagan2, Kavin Fatehchand2, Payal Mehta2, Andrew Stiff2, Brenda F Reader2, Xiaokui Mo3, John C Byrd2, William E Carson2, Jonathan P Butchar4, Susheela Tridandapani5.   

Abstract

The irreversible Bruton's tyrosine kinase (Btk) inhibitor ibrutinib has shown efficacy against B-cell tumors such as chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma. Fcγ receptors (FcγR) on immune cells such as macrophages play an important role in tumor-specific antibody-mediated immune responses, but many such responses involve Btk. Here we tested the effects of ibrutinib on FcγR-mediated activities in monocytes. We found that ibrutinib did not affect monocyte FcγR-mediated phagocytosis, even at concentrations higher than those achieved physiologically, but suppressed FcγR-mediated cytokine production. We confirmed these findings in macrophages from Xid mice in which Btk signaling is defective. Because calcium flux is a major event downstream of Btk, we tested whether it was involved in phagocytosis. The results showed that blocking intracellular calcium flux decreased FcγR-mediated cytokine production but not phagocytosis. To verify this, we measured activation of the GTPase Rac, which is responsible for actin polymerization. Results showed that ibrutinib did not inhibit Rac activation, nor did the calcium chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid tetrakis(acetoxymethyl ester). We next asked whether the effect of ibrutinib on monocyte FcγR-mediated cytokine production could be rescued by IFNγ priming because NK cells produce IFNγ in response to antibody therapy. Pretreatment of monocytes with IFNγ abrogated the effects of ibrutinib on FcγR-mediated cytokine production, suggesting that IFNγ priming could overcome this Btk inhibition. Furthermore, in monocyte-natural killer cell co-cultures, ibrutinib did not inhibit FcγR-mediated cytokine production despite doing so in single cultures. These results suggest that combining ibrutinib with monoclonal antibody therapy could enhance chronic lymphocytic leukemia cell killing without affecting macrophage effector function.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Btk; Fcγ receptor; cancer therapy; ibrutinib; immunotherapy; interferon; monocyte; signal transduction

Mesh:

Substances:

Year:  2015        PMID: 26627823      PMCID: PMC4742765          DOI: 10.1074/jbc.M115.687251

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

1.  Bruton's tyrosine kinase deficiency in macrophages inhibits nitric oxide generation leading to enhancement of IL-12 induction.

Authors:  S Mukhopadhyay; A George; V Bal; B Ravindran; S Rath
Journal:  J Immunol       Date:  1999-08-15       Impact factor: 5.422

Review 2.  Btk function in B cell development and response.

Authors:  A B Satterthwaite; Z Li; O N Witte
Journal:  Semin Immunol       Date:  1998-08       Impact factor: 11.130

3.  Delayed clearance of filarial infection and enhanced Th1 immunity due to modulation of macrophage APC functions in xid mice.

Authors:  S Mukhopadhyay; P K Sahoo; A George; V Bal; S Rath; B Ravindran
Journal:  J Immunol       Date:  1999-07-15       Impact factor: 5.422

4.  Immunoglobulin G-mediated phagocytosis activates a calcium-independent, phosphatidylethanolamine-specific phospholipase.

Authors:  M R Lennartz; J B Lefkowith; F A Bromley; E J Brown
Journal:  J Leukoc Biol       Date:  1993-11       Impact factor: 4.962

5.  Aggregated immunoglobulin protects immune T cells from suppression: dependence on isotype, Fc portion, and macrophage FcgammaR.

Authors:  W Ptak; V Paliwal; K Bryniarski; M Ptak; P W Askenase
Journal:  Scand J Immunol       Date:  1998-02       Impact factor: 3.487

6.  Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.

Authors:  Samantha M Jaglowski; Jeffrey A Jones; Veena Nagar; Joseph M Flynn; Leslie A Andritsos; Kami J Maddocks; Jennifer A Woyach; Kristie A Blum; Michael R Grever; Kelly Smucker; Amy S Ruppert; Nyla A Heerema; Gerard Lozanski; Mona Stefanos; Brian Munneke; Jamie-Sue West; Jutta K Neuenburg; Danelle F James; Nathan Hall; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2015-06-26       Impact factor: 22.113

7.  Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes.

Authors:  J D Thomas; P Sideras; C I Smith; I Vorechovský; V Chapman; W E Paul
Journal:  Science       Date:  1993-07-16       Impact factor: 47.728

8.  Defective degranulation and calcium mobilization of bone-marrow derived mast cells from Xid and Btk-deficient mice.

Authors:  R Setoguchi; T Kinashi; H Sagara; K Hirosawa; K Takatsu
Journal:  Immunol Lett       Date:  1998-12       Impact factor: 3.685

9.  Protein kinase C activation precedes arachidonic acid release during IgG-mediated phagocytosis.

Authors:  K Karimi; M R Lennartz
Journal:  J Immunol       Date:  1995-12-15       Impact factor: 5.422

10.  The pleckstrin homology domain of Bruton tyrosine kinase interacts with protein kinase C.

Authors:  L Yao; Y Kawakami; T Kawakami
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

View more
  31 in total

1.  IL-6/p-BTK/p-ERK signaling mediates calcium phosphate-induced pruritus.

Authors:  Sunita Keshari; Chien-Lung Chen; Apriska Dewi Sipayung; Ching-Chuan Hsieh; Li-Jen Su; Yun-Ru Chiang; Huan-Cheng Chang; Wu-Chang Yang; Tsung-Hsien Chuang; Chun-Ming Huang
Journal:  FASEB J       Date:  2019-07-31       Impact factor: 5.191

Review 2.  Inhibiting Bruton's Tyrosine Kinase in CLL and Other B-Cell Malignancies.

Authors:  Fabienne Lucas; Jennifer A Woyach
Journal:  Target Oncol       Date:  2019-04       Impact factor: 4.493

3.  Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia.

Authors:  Jorge J Castillo; Joshua N Gustine; Kirsten Meid; Toni Dubeau; Patricia Severns; Steven P Treon
Journal:  Haematologica       Date:  2018-02-22       Impact factor: 9.941

4.  Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy.

Authors:  V K Patel; B Lamothe; M L Ayres; J Gay; J P Cheung; K Balakrishnan; C Ivan; J Morse; M Nelson; M J Keating; W G Wierda; J R Marszalek; V Gandhi
Journal:  Leukemia       Date:  2017-11-03       Impact factor: 11.528

5.  CD31 Acts as a Checkpoint Molecule and Is Modulated by FcγR-Mediated Signaling in Monocytes.

Authors:  Giovanna Merchand-Reyes; Frank H Robledo-Avila; Nathaniel J Buteyn; Shalini Gautam; Ramasamy Santhanam; Kavin Fatehchand; Xiaokui Mo; Santiago Partida-Sanchez; Jonathan P Butchar; Susheela Tridandapani
Journal:  J Immunol       Date:  2019-11-15       Impact factor: 5.422

6.  Disruption of Nurse-like Cell Differentiation as a Therapeutic Strategy for Chronic Lymphocytic Leukemia.

Authors:  Giovanna Merchand-Reyes; Ramasamy Santhanam; Frank H Robledo-Avila; Christoph Weigel; Juan de Dios Ruiz-Rosado; Xiaokui Mo; Santiago Partida-Sánchez; Jennifer A Woyach; Christopher C Oakes; Susheela Tridandapani; Jonathan P Butchar
Journal:  J Immunol       Date:  2022-08-22       Impact factor: 5.426

7.  Using Informatics Tools to Identify Opportunities for Precision Medicine in Diffuse Large B-cell Lymphoma.

Authors:  Sharvil P Patel; R Andrew Harkins; Michelle J Lee; Christopher R Flowers; Jean L Koff
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-12-24

Review 8.  Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia.

Authors:  Christopher Pleyer; Adrian Wiestner; Clare Sun
Journal:  Leuk Lymphoma       Date:  2018-05-15

Review 9.  Targeting Bruton's Tyrosine Kinase in Inflammatory and Autoimmune Pathologies.

Authors:  Stefan F H Neys; Rudi W Hendriks; Odilia B J Corneth
Journal:  Front Cell Dev Biol       Date:  2021-06-04

Review 10.  BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects.

Authors:  Marzia Palma; Tom A Mulder; Anders Österborg
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.